Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
Completed · Phase 3 · NCT05146999
Conditions: Glabellar Frown Lines
At a glance
- Research payments reported, 2025
- $1,500
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 132
About the trial
- Sponsor
- Galderma R&D
- Tested
- QM1114-DP (biological), Placebo (biological)
- Dates
- Started 2022-05-09; completion 2023-09-01
- Results posted
- Yes
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
From ClinicalTrials.gov, last updated 2024-10-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Galderma Laboratories, L.P. reported $1,500 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Glynis R. Ablon, M.D. Dermatology · Manhattan Beach, CA
- Edward L. Lain, M.D. Dermatology · Austin, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Conash Or Inc $1,000
- Austin Institute for Clinical Research Inc $500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.